A randomised, placebo-controlled, double-blind study of adjuvant Cemiplimab versus placebo after surgery and radiation therapy in patients with high risk cutaneous squamous cell carcinoma
Primary Sponsor
Collaborating Groups
TROG Cancer Research
Accrual Target
412
Final Accrual
415
Closing Date of Accrual
20 August 2024
Trial Chairperson
Prof Sandro Porceddu - Princess Alexandra Hospital
Trial Contact
qa@trog.com.au
Related Post
5 December, 2024
Extended follow-up of TROG 99.03 lymphoma trial published
5 December 2024: Study shows huge improvement in progression-free
28 November, 2024
Meet TROG President: A/Prof Puma Sandaresan
28 November 2024: In this Q&A, TROG President A/Prof
